# To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain

> **NCT04647773** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 687 (estimated)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** HSK16149 20mg BID
- **DRUG:** HSK16149 40mg BID
- **DRUG:** HSK16149 60mg BID
- **DRUG:** HSK16149 80mg BID
- **DRUG:** Pregabalin 150mg BID
- **DRUG:** Placebo BID

## Key facts

- **NCT ID:** NCT04647773
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-02
- **Primary completion:** 2022-11-09
- **Final completion:** 2022-11-16
- **Target enrollment:** 687 (ESTIMATED)
- **Last updated:** 2020-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04647773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04647773, "To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04647773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*